Download Publikationen Martin Fassnacht (Stand Januar 2015) 1. Reincke M

Publikationen Martin Fassnacht (Stand Januar 2015)
1.
Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger
T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, Tanaka K, Wieland T, Graf E, Saeger W, Ronchi
CL, Allolio B, Buchfelder M, Strom TM, Fassnacht M, Komada M 2015 Mutations in the
deubiquitinase gene USP8 cause Cushing's disease. Nat Genet 47:31-38
2.
Deutschbein T, Fassnacht M, Weismann D, Reincke M, Mann K, Petersenn S 2015
Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide,
vincristine and dacarbazine: own experience and overview of the contemporary literature.
Clin Endocrinol (Oxf) 82:84-90
3.
Faria AM, Sbiera S, Ribeiro TC, Soares IC, Mariani BM, Freire DS, de Sousa GR, Lerario AM,
Ronchi CL, Deutschbein T, Wakamatsu A, Alves VA, Zerbini MC, Mendonca BB, Fragoso MC,
Latronico AC, Fassnacht M, Almeida MQ 2014 Expression of LIN28 and its regulatory
microRNAs in adult adrenocortical cancer. Clin Endocrinol (Oxf)
4.
Ronchi CL, Sbiera S, Volante M, Steinhauer S, Scott-Wild V, Altieri B, Kroiss M, Bala M,
Papotti M, Deutschbein T, Terzolo M, Fassnacht M, Allolio B 2014 CYP2W1 is highly
expressed in adrenal glands and is positively associated with the response to mitotane in
adrenocortical carcinoma. PLoS One 9:e105855
5.
Eisenhofer G, Brown S, Peitzsch M, Pelzel D, Lattke P, Glockner S, Stell A, Prejbisz A,
Fassnacht M, Beuschlein F, Januszewicz A, Siegert G, Reichmann H 2014 Levodopa therapy
in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometricbased measurements of plasma and urinary normetanephrine, metanephrine and
methoxytyramine. Ann Clin Biochem 51:38-46
6.
Corteville C, Fassnacht M, Bueter M 2014 [Surgery as pluripotent instrument for metabolic
disease. What are the mechanisms?]. Chirurg 85:963-968
7.
Ronchi CL, Kroiss M, Sbiera S, Deutschbein T, Fassnacht M 2014 EJE prize 2014: current and
evolving treatment options in adrenocortical carcinoma: where do we stand and where do
we want to go? Eur J Endocrinol 171:R1-R11
8.
Di Dalmazi G, Berr CM, Fassnacht M, Beuschlein F, Reincke M 2014 Adrenal function after
adrenalectomy for subclinical hypercortisolism and Cushing's syndrome: a systematic
review of the literature. J Clin Endocrinol Metab 99:2637-2645
9.
Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S,
Perlemoine K, Rene-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler
M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E,
Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F,
Libe R, de Reynies A, Bertherat J 2014 Integrated genomic characterization of
adrenocortical carcinoma. Nat Genet 46:607-612
10.
Baecher S, Kroiss M, Fassnacht M, Vogeser M 2014 No endogenous ouabain is detectable in
human plasma by ultra-sensitive UPLC-MS/MS. Clin Chim Acta 431:87-92
11.
Sue M, Martucci V, Frey F, Lenders J, Timmers HJ, Peczkowska M, Prejbisz A, Swantje B,
Bornstein SR, Arlt W, Fassnacht M, Beuschlein F, Robledo M, Pacak K, Eisenhofer G 2014
Lack of Utility of SDHB Mutation Testing in Adrenergic Metastatic Phaeochromocytoma. Eur
J Endocrinol
12.
Weismann D, Peitzsch M, Raida A, Prejbisz A, Gosk M, Riester A, Willenberg HS, Klemm R,
Manz G, Deutschbein T, Kroiss M, Darr R, Bidlingmaier M, Januszewicz A, Eisenhofer G,
Fassnacht M 2014 Measurements of Plasma Metanephrines by Immunoassay versus LCMS/MS for Diagnosis of Pheochromocytoma. Eur J Endocrinol
13.
Heinze B, Herrmann LJ, Fassnacht M, Ronchi CL, Willenberg HS, Quinkler M, Reisch N, Zink
M, Allolio B, Hahner S 2014 Less common genotype variants of TP53 polymorphisms are
associated with poor outcome in adult patients with adrenocortical carcinoma. Eur J
Endocrinol 170:707-717
14.
Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, Williams
AR, Ardito A, Leboulleux S, Volante M, Deutschbein T, Feelders R, Ronchi C, Grisanti S,
Gelderblom H, Porpiglia F, Papotti M, Hammer GD, Allolio B, Terzolo M 2014 Prognostic role
of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur
Urol 65:832-838
15.
Weismann D, Liu D, Bergen T, Peitzsch M, Raida A, Wagner M, Fassnacht M, Weidemann F,
Allolio B 2014 Hypertension and hypertensive cardiomyopathy in patients with a relapsefree history of phaeochromocytoma. Clin Endocrinol (Oxf)
16.
Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, Quinkler M, Rayes N,
Tabarin A, Laure Jullie M, Mantero F, Rubin B, Waldmann J, Bartsch DK, Pasquali R, Lohse
M, Allolio B, Fassnacht M, Beuschlein F, Reincke M 2014 Novel somatic mutations in the
catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a
European multicentric study. J Clin Endocrinol Metab 99:E2093-2100
17.
Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland
T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, RizkRabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S,
Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B 2014 Constitutive
activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med 370:10191028
18.
Fenske WK, Christ-Crain M, Horning A, Simet J, Szinnai G, Fassnacht M, Rutishauser J, Bichet
DG, Stork S, Allolio B 2014 A copeptin-based classification of the osmoregulatory defects in
the syndrome of inappropriate antidiuresis. J Am Soc Nephrol 25:2376-2383
19.
Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K, Milovanovic D, Beuschlein F,
Willenberg HS, Quinkler M, Allolio B 2014 High incidence of adrenal crisis in educated
patients with chronic adrenal insufficiency - a prospective study. J Clin Endocrinol
Metab:jc20143191
20.
Drechsler C, Schneider A, Gutjahr-Lengsfeld L, Kroiss M, Carrero JJ, Krane V, Allolio B,
Wanner C, Fassnacht M 2014 Thyroid function, cardiovascular events, and mortality in
diabetic hemodialysis patients. Am J Kidney Dis 63:988-996
21.
Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel U, Ronchi C, Beuschlein F, Reincke M,
Lorenz K, Allolio B, Kisker C, Fassnacht M, Lohse MJ 2014 PKA catalytic subunit mutations in
adrenocortical Cushing's adenoma impair association with the regulatory subunit. Nat
Commun 5:5680
22.
Jurowich CF, Seyfried F, Miras AD, Bueter M, Deckelmann J, Fassnacht M, Germer CT,
Thalheimer A 2014 Does bariatric surgery change olfactory perception? Results of the early
postoperative course. Int J Colorectal Dis 29:253-260
23.
Fassnacht M, Kroiss M, Allolio B 2013 Update in adrenocortical carcinoma. J Clin Endocrinol
Metab 98:4551-4564
24.
Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid B,
Leboulleux S, Mantero F, Haak HR, Fassnacht M 2013 Comparison of two mitotane starting
dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab
98:4759-4767
25.
Verburg FA, Reiners C, Grelle I, Barth H, Fassnacht M, Luster M 2013 Calcium stimulated
calcitonin measurement: a procedural proposal. Exp Clin Endocrinol Diabetes 121:318-320
26.
Jurowich C, Fassnacht M, Kroiss M, Deutschbein T, Germer CT, Reibetanz J 2013 Is there a
role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma?
A critical appraisal of the literature. Horm Metab Res 45:130-136
27.
Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Guder G, Ertl G, Angermann CE, Stork S,
Fassnacht M 2013 Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J
Cardiol 168:300-305
28.
Weismann D, Pelka T, Bender G, Jurowich C, Fassnacht M, Thalheimer A, Allolio B 2013
Bariatric surgery for morbid obesity in craniopharyngioma. Clin Endocrinol (Oxf) 78:385-390
29.
Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA,
deVries JH, Zaggia B, De Francia S, Volante M, Haak HR, Allolio B, Al Ghuzlan A, Fassnacht
M, Berruti A 2013 Mitotane levels predict the outcome of patients with adrenocortical
carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 169:263-270
30.
Sbiera S, Kroiss M, Thamm T, Beyer M, Majidi F, Kuehner D, Wobser M, Becker JC, Adam P,
Ronchi C, Allolio B, Fassnacht M 2013 Survivin in adrenocortical tumors - pathophysiological
implications and therapeutic potential. Horm Metab Res 45:137-146
31.
Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, Knoedler P, Lang K,
Reiners C, Buck AK, Allolio B, Schirbel A 2013 Functional characterization of adrenal lesions
using [123I]IMTO-SPECT/CT. J Clin Endocrinol Metab 98:1508-1518
32.
Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libe R, Allolio B,
Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F,
Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CH,
Stewart PM, Hahner S, Arlt W 2013 Mitotane therapy in adrenocortical cancer induces
CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid
and androgen replacement. J Clin Endocrinol Metab 98:161-171
33.
Ronchi CL, Sbiera S, Leich E, Henzel K, Rosenwald A, Allolio B, Fassnacht M 2013 Single
nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an
adenoma carcinoma sequence? PLoS One 8:e73959
34.
Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schonfeld S, Blouin K, Bidlingmaier M, Hammer F,
Krane V, Marz W, Allolio B, Fassnacht M, Wanner C 2013 Aldosterone and cortisol affect
the risk of sudden cardiac death in haemodialysis patients. Eur Heart J 34:578-587
35.
Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J,
Willenberg HS, Beuschlein F, Fottner C, Klose S, Heidemeier A, Brix D, Fenske W, Hahner S,
Reibetanz J, Allolio B, Fassnacht M, German Adrenocortical Carcinoma Study G 2013 The
role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol
Metab 98:181-191
36.
Peitzsch M, Pelzel D, Glockner S, Prejbisz A, Fassnacht M, Beuschlein F, Januszewicz A,
Siegert G, Eisenhofer G 2013 Simultaneous liquid chromatography tandem mass
spectrometric determination of urinary free metanephrines and catecholamines, with
comparisons of free and deconjugated metabolites. Clin Chim Acta 418:50-58
37.
Reibetanz J, Jurowich C, Allolio B, Fassnacht M, Fassnacht M 2013 Reply to letter: "regional
lymphadenectomy for adrenocortical carcinoma". Ann Surg 257:e15
38.
Kreissl MC, Schirbel A, Fassnacht M, Haenscheid H, Verburg FA, Bock S, Saeger W, Knoedler
P, Reiners C, Buck AK, Allolio B, Hahner S 2013 [(1)(2)(3)I]Iodometomidate imaging in
adrenocortical carcinoma. J Clin Endocrinol Metab 98:2755-2764
39.
Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F, Sperone P,
Scagliotti G, Allolio B, Papotti M, Berruti A 2012 Ribonucleotide reductase large subunit
(RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
Clin Cancer Res 18:3452-3461
40.
Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin
PF 2012 Long-term postoperative follow-up in patients with apparently benign
pheochromocytoma and paraganglioma. Horm Metab Res 44:385-389
41.
Ronchi CL, Leich E, Sbiera S, Weismann D, Rosenwald A, Allolio B, Fassnacht M 2012 Single
nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas
identifies new candidate genes and pathways. Neoplasia 14:206-218
42.
Hammer GD, Fassnacht M, Lalli E 2012 Adrenal cancer: scientific advances. Mol Cell
Endocrinol 351:1
43.
Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K,
Strasburger CJ, Hahner S, Muller HH, Allolio B, Fassnacht M 2012 Sunitinib in refractory
adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab
97:3495-3503
44.
Ronchi CL, Sbiera S, Leich E, Tissier F, Steinhauer S, Deutschbein T, Fassnacht M, Allolio B
2012 Low SGK1 expression in human adrenocortical tumors is associated with ACTHindependent glucocorticoid secretion and poor prognosis. J Clin Endocrinol Metab
97:E2251-2260
45.
Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C,
Allolio B, Schirbel A 2012 [131I]iodometomidate for targeted radionuclide therapy of
advanced adrenocortical carcinoma. J Clin Endocrinol Metab 97:914-922
46.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C,
Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M,
Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler
M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F,
Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B,
Group F-AS 2012 Combination chemotherapy in advanced adrenocortical carcinoma. N Engl
J Med 366:2189-2197
47.
Reibetanz J, Kroiss M, Deutschbein T, Fenske W, Gasser M, Jurowich C, Germer CT, Allolio B,
Fassnacht M 2012 [German adrenocortical carcinoma registry. Surgical therapy results and
follow-up treatment]. Chirurg 83:528-535
48.
Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M, Allolio B,
Hahner S 2012 TP53 germline mutations in adult patients with adrenocortical carcinoma. J
Clin Endocrinol Metab 97:E476-485
49.
Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, Behrend M, Allolio B,
Fassnacht M, German ACCsg 2012 Impact of lymphadenectomy on the oncologic outcome
of patients with adrenocortical carcinoma. Ann Surg 255:363-369
50.
Waldmann J, Patsalis N, Fendrich V, Langer P, Saeger W, Chaloupka B, Ramaswamy A,
Fassnacht M, Bartsch DK, Slater EP 2012 Clinical impact of TP53 alterations in
adrenocortical carcinomas. Langenbecks Arch Surg 397:209-216
51.
Schirpenbach C, Hoppert T, Aleksic I, Neumann HP, Hahner S, Fassnacht M, Allolio B 2012
[A 47-year-old patient with paroxysmal arterial hypertension and gastric tumors]. Internist
(Berl) 53:1119-1124
52.
Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G,
Group EGW 2012 Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol 23 Suppl 7:vii131-138
53.
Couture C, Saveanu A, Barlier A, Carel JC, Fassnacht M, Fluck CE, Houang M, Maes M, PhanHug F, Enjalbert A, Drouin J, Brue T, Vallette S 2012 Phenotypic homogeneity and genotypic
variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene
mutations. J Clin Endocrinol Metab 97:E486-495
54.
Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F,
Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E 2011 Plasma
concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to
mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J
Clin Endocrinol Metab 96:1844-1851
55.
Uhmann A, van den Brandt J, Dittmann K, Hess I, Dressel R, Binder C, Luhder F, Christiansen
H, Fassnacht M, Bhandoola A, Wienands J, Reichardt HM, Hahn H 2011 T cell development
critically depends on prethymic stromal patched expression. J Immunol 186:3383-3391
56.
Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, Schneider P, Smith DJ, Stiekema H,
Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P,
Shackleton CH, Bertagna X, Fassnacht M, Stewart PM 2011 Urine steroid metabolomics as a
biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab
96:3775-3784
57.
op den Winkel J, Pfannschmidt J, Muley T, Grunewald C, Dienemann H, Fassnacht M, Allolio
B 2011 Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in
24 patients. Ann Thorac Surg 92:1965-1970
58.
Lesch KP, Selch S, Renner TJ, Jacob C, Nguyen TT, Hahn T, Romanos M, Walitza S, Shoichet
S, Dempfle A, Heine M, Boreatti-Hummer A, Romanos J, Gross-Lesch S, Zerlaut H, Wultsch
T, Heinzel S, Fassnacht M, Fallgatter A, Allolio B, Schafer H, Warnke A, Reif A, Ropers HH,
Ullmann R 2011 Genome-wide copy number variation analysis in attentiondeficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended
pedigree. Mol Psychiatry 16:491-503
59.
Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M 2011 Drug interactions with mitotane
by induction of CYP3A4 metabolism in the clinical management of adrenocortical
carcinoma. Clin Endocrinol (Oxf) 75:585-591
60.
Hammer GD, Fassnacht M, Lalli E 2011 Adrenal cancer: clinical advances. Horm Cancer
2:323
61.
Fassnacht M, Libe R, Kroiss M, Allolio B 2011 Adrenocortical carcinoma: a clinician's update.
Nat Rev Endocrinol 7:323-335
62.
Ronchi CL, Verrua E, Ferrante E, Bender G, Sala E, Lania AG, Fassnacht M, Beck-Peccoz P,
Allolio B, Spada A, Arosio M 2011 Long-term effects of radiotherapy on cardiovascular risk
factors in acromegaly. Eur J Endocrinol 164:675-684
63.
Kroiss M, Reuss M, Kuhner D, Johanssen S, Beyer M, Zink M, Hartmann MF, Dhir V, Wudy
SA, Arlt W, Sbiera S, Allolio B, Fassnacht M 2011 Sunitinib Inhibits Cell Proliferation and
Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells.
Front Endocrinol (Lausanne) 2:27
64.
Zini L, Porpiglia F, Fassnacht M 2011 Contemporary management of adrenocortical
carcinoma. Eur Urol 60:1055-1065
65.
Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, Pfeiffer AF, Fassnacht
M, Stork S, Allolio B 2011 Copeptin in the differential diagnosis of the polydipsia-polyuria
syndrome--revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab
96:1506-1515
66.
Sbiera S, Dexneit T, Reichardt SD, Michel KD, van den Brandt J, Schmull S, Kraus L, Beyer M,
Mlynski R, Wortmann S, Allolio B, Reichardt HM, Fassnacht M 2011 Influence of short-term
glucocorticoid therapy on regulatory T cells in vivo. PLoS One 6:e24345
67.
Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA,
Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hufner M, Wohllk N, Opocher G, Dvorakova
S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorlander C, Maia AL,
Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J,
Damjanovic S, Muresan M, Wuster C, Fassnacht M, Peczkowska M, Fauth C, Golcher H,
Walter MA, Pichl J, Raue F, Eng C, Neumann HP, International RETEC 2011 Risk profiles and
penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET
mutations located in exon 10. Hum Mutat 32:51-58
68.
Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audebourg A,
Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J, Tissier F
2011 beta-catenin activation is associated with specific clinical and pathologic
characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 17:328336
69.
Gruber M, Eisenhofer G, Fassnacht M, Bornstein SR 2011 [Recent advances in adrenal
diseases]. Dtsch Med Wochenschr 136:1998-2001
70.
Willhauck MJ, Schott M, Kreissl MC, Fassnacht M, Spitzweg C 2011 [New therapeutic
options for advanced thyroid cancer]. Dtsch Med Wochenschr 136:1165-1168
71.
Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Fuhrer D,
Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B, German ACCRG 2010
Improved survival in patients with stage II adrenocortical carcinoma followed up
prospectively by specialized centers. J Clin Endocrinol Metab 95:4925-4932
72.
Fassnacht M, Wittekind C, Allolio B 2010 [Current TNM classification systems for
adrenocortical carcinoma]. Pathologe 31:374-378
73.
Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, Ventz M,
Quinkler M, Allolio B 2010 Epidemiology of adrenal crisis in chronic adrenal insufficiency:
the need for new prevention strategies. Eur J Endocrinol 162:597-602
74.
Adam P, Hahner S, Hartmann M, Heinrich B, Quinkler M, Willenberg HS, Saeger W, Sbiera S,
Schmull S, Voelker HU, Strobel P, Allolio B, Fassnacht M 2010 Epidermal growth factor
receptor in adrenocortical tumors: analysis of gene sequence, protein expression and
correlation with clinical outcome. Mod Pathol 23:1596-1604
75.
Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, Kroiss M,
Jurowich C, Langer P, Oelkers W, Spahn M, Willenberg HS, Mader U, Allolio B, Fassnacht M
2010 Deficits in the management of patients with adrenocortical carcinoma in Germany.
Dtsch Arztebl Int 107:885-891
76.
Quinkler M, Fassnacht M, Petersenn S, Reisch N, Willenberg HS, Diederich S 2010
[Pheochromocytoma: current diagnostics and treatment]. MMW Fortschr Med 152:36-38
77.
Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F,
Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M 2010 High diagnostic
and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin
Endocrinol Metab 95:E161-171
78.
Hahner S, Sturmer A, Fassnacht M, Hartmann RW, Schewe K, Cochran S, Zink M, Schirbel A,
Allolio B 2010 Etomidate unmasks intraadrenal regulation of steroidogenesis and
proliferation in adrenal cortical cell lines. Horm Metab Res 42:528-534
79.
Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, Akker SA,
Drake WM, Edwards R, Allolio B, Grossman AB 2010 Assessment of serum-free cortisol
levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin
Endocrinol (Oxf) 72:305-311
80.
Weismann D, Kleinbrahm K, Hu K, Fassnacht M, Frantz S, Ertl G, Allolio B, Maier SK 2010
Prevention of hypertensive crises in rats induced by acute and chronic norepinephrine
excess. Horm Metab Res 42:803-808
81.
Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B,
Terzolo M 2010 Adjuvant therapy in patients with adrenocortical carcinoma: a position of
an international panel. J Clin Oncol 28:e401-402; author reply e403
82.
Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C,
Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M, German Adrenocortical
Carcinoma Registry G 2010 Laparoscopic versus open adrenalectomy for adrenocortical
carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609-615
83.
Fassnacht M, Allolio B 2010 What is the best approach to an apparently nonmetastatic
adrenocortical carcinoma? Clin Endocrinol (Oxf) 73:561-565
84.
Fassnacht M, Beuschlein F, Quinkler M, Petersenn S 2010 [Arterial hypertension and
subclinical Cushing's syndrome]. MMW Fortschr Med 152:39-41
85.
Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B, Fassnacht M
2010 Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical
carcinoma. Eur J Endocrinol 162:349-356
86.
Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, Ventz M,
Beuschlein F, Reincke M, Reisch N, Quinkler M 2009 Frequent incidental discovery of
phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J
Endocrinol 161:355-361
87.
Fassnacht M, Kreissl MC, Weismann D, Allolio B 2009 New targets and therapeutic
approaches for endocrine malignancies. Pharmacol Ther 123:117-141
88.
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M,
Mueller HH, Hahner S, Allolio B, German Adrenocortical Carcinoma Registry G, European
Network for the Study of Adrenal T 2009 Limited prognostic value of the 2004 International
Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a
Revised TNM Classification. Cancer 115:243-250
89.
Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C,
Morange I, Pico A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B 2009
Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 160:1003-1010
90.
Weismann D, Briese J, Niemann J, Gruneberger M, Adam P, Hahner S, Johanssen S, Liu W,
Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger
CM 2009 Osteopontin stimulates invasion of NCI-h295 cells but is not associated with
survival in adrenocortical carcinoma. J Pathol 218:232-240
91.
Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, Kenn W,
Hahner S, Allolio B, Flentje M 2009 Radiotherapy in adrenocortical carcinoma. Cancer
115:2816-2823
92.
Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A 2009 Adjuvant mitotane for
adrenocortical cancer--working through uncertainty. J Clin Endocrinol Metab 94:1879-1880
93.
Fassnacht M, Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Pract
Res Clin Endocrinol Metab 23:273-289
94.
Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Mussig K, Muresan M,
Schaffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F,
Plockinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK,
Eng C, Neumann HP, European-American Pheochromocytoma Study G 2009 Clinical
predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin
Cancer Res 15:6378-6385
95.
Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S,
Allolio B, Fassnacht M 2009 Expression of excision repair cross complementing group 1 and
prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Endocr Relat Cancer 16:907-918
96.
Doyle P, Duren C, Nerlich K, Verburg FA, Grelle I, Jahn H, Fassnacht M, Mader U, Reiners C,
Luster M 2009 Potency and tolerance of calcitonin stimulation with high-dose calcium
versus pentagastrin in normal adults. J Clin Endocrinol Metab 94:2970-2974
97.
Fenske W, Volker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M,
Muller-Hermelink HK, Allolio B, Fassnacht M 2009 Glucose transporter GLUT1 expression is
an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr
Relat Cancer 16:919-928
98.
Sbiera S, Wortmann S, Fassnacht M 2008 Dendritic cell based immunotherapy--a promising
therapeutic approach for endocrine malignancies. Horm Metab Res 40:89-98
99.
Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Ruckauer KD,
Beuschlein F 2008 Side population does not define stem cell-like cancer cells in the
adrenocortical carcinoma cell line NCI h295R. Endocrinology 149:1314-1322
100.
Lim HY, van den Brandt J, Fassnacht M, Allolio B, Herold MJ, Reichardt HM 2008 Silencing of
the mineralocorticoid receptor by ribonucleic acid interference in transgenic rats disrupts
endocrine homeostasis. Mol Endocrinol 22:1304-1311
101.
Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B,
Fassnacht M 2008 Treatment of advanced adrenocortical carcinoma with erlotinib plus
gemcitabine. J Clin Endocrinol Metab 93:2057-2062
102.
Frantz S, Fassnacht M, Allolio B, Bauersachs J 2008 [Obesity and heart failure]. Internist
(Berl) 49:389-390, 392-383
103.
Johanssen S, Fassnacht M, Brix D, Koschker AC, Hahner S, Riedmiller H, Allolio B 2008
[Adrenocortical carcinoma. Diagnostic work-up and treatment]. Urologe A 47:172-181
104.
Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, Beuschlein F, Zink
M, Lang K, Allolio B, Schirbel A 2008 [123 I]Iodometomidate for molecular imaging of
adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab 93:23582365
105.
Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E 2007 Vaccination against the
forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67:371380
106.
Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt
W, Allolio B 2007 Impaired subjective health status in 256 patients with adrenal
insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab
92:3912-3922
107.
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L,
Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S,
Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F,
Allolio B, Dogliotti L, Berruti A 2007 Adjuvant mitotane treatment for adrenocortical
carcinoma. N Engl J Med 356:2372-2380
108.
Coll AP, Fassnacht M, Klammer S, Hahner S, Schulte DM, Piper S, Tung YC, Challis BG,
Weinstein Y, Allolio B, O'Rahilly S, Beuschlein F 2006 Peripheral administration of the Nterminal pro-opiomelanocortin fragment 1-28 to Pomc-/- mice reduces food intake and
weight but does not affect adrenal growth or corticosterone production. J Endocrinol
190:515-525
109.
Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B 2006 Adrenocortical carcinoma
-- improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes
114:45-51
110.
Weismann D, Fassnacht M, Weinberger F, Hamelmann W, Diehl S, Lorenz K, Baerlehner E,
Reincke M, Beuschlein F, Knoefel W, Nies C, Hahner S, Allolio B 2006 Intraoperative
haemodynamic stability in patients with phaeochromocytoma--minimally invasive vs
conventional open surgery. Clin Endocrinol (Oxf) 65:352-358
111.
Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B 2006 Efficacy of
adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J
Clin Endocrinol Metab 91:4501-4504
112.
Weismann D, Fassnacht M, Schubert B, Bonfig R, Tschammler A, Timm S, Hahner S, Wunder
C, Allolio B 2006 A dangerous liaison--pheochromocytoma in patients with malignant
disease. Ann Surg Oncol 13:1696-1701
113.
Papewalis C, Fassnacht M, Willenberg HS, Domberg J, Fenk R, Rohr UP, Schinner S,
Bornstein SR, Scherbaum WA, Schott M 2006 Dendritic cells as potential adjuvant for
immunotherapy in adrenocortical carcinoma. Clin Endocrinol (Oxf) 65:215-222
114.
Allolio B, Fassnacht M 2006 Clinical review: Adrenocortical carcinoma: clinical update. J Clin
Endocrinol Metab 91:2027-2037
115.
Bausch B, Koschker AC, Fassnacht M, Stoevesandt J, Hoffmann MM, Eng C, Allolio B,
Neumann HP 2006 Comprehensive mutation scanning of NF1 in apparently sporadic cases
of pheochromocytoma. J Clin Endocrinol Metab 91:3478-3481
116.
Saeger W, Fassnacht M 2006 [Effects of drugs on the adrenal cortex and its tumors].
Pathologe 27:61-64
117.
Vallette-Kasic S, Brue T, Pulichino AM, Gueydan M, Barlier A, David M, Nicolino M,
Malpuech G, Dechelotte P, Deal C, Van Vliet G, De Vroede M, Riepe FG, Partsch CJ, Sippell
WG, Berberoglu M, Atasay B, de Zegher F, Beckers D, Kyllo J, Donohoue P, Fassnacht M,
Hahner S, Allolio B, Noordam C, Dunkel L, Hero M, Pigeon B, Weill J, Yigit S, Brauner R,
Heinrich JJ, Cummings E, Riddell C, Enjalbert A, Drouin J 2005 Congenital isolated
adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by
TPIT gene mutations. J Clin Endocrinol Metab 90:1323-1331
118.
Hahner S, Fassnacht M, Hammer F, Schammann M, Weismann D, Hansen IA, Allolio B 2005
Evidence against a role of human airway trypsin-like protease--the human analogue of the
growth-promoting rat adrenal secretory protease--in adrenal tumourigenesis. Eur J
Endocrinol 152:143-153
119.
Hahner S, Fassnacht M 2005 Mitotane for adrenocortical carcinoma treatment. Curr Opin
Investig Drugs 6:386-394
120.
Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E 2005 Induction of CD4(+)
and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein:
implication for cancer immunotherapy. Clin Cancer Res 11:5566-5571
121.
Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, Hahner S, Allolio B 2005
AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical
tumors. J Clin Endocrinol Metab 90:4366-4370
122.
Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E 2005 Tumor immunotherapy targeting
fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer
Res 65:11156-11163
123.
Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F, German, Austrian
Adrenal N 2005 Peroxisome proliferator-activated receptor-gamma agonists suppress
adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab
90:3886-3896
124.
Allolio B, Hahner S, Weismann D, Fassnacht M 2004 Management of adrenocortical
carcinoma. Clin Endocrinol (Oxf) 60:273-287
125.
Vallette-Kasic S, Pulichino AM, Gueydan M, Barlier A, David M, Malpuech G, Deal C, Van
Vliet G, de Vroede M, Riepe F, Partsch CJ, Sippell W, Berberoglu M, Atasay B, de Zegher F,
Kyllo J, Donohoue P, Dechelotte P, Fassnacht M, Noordam K, Dunkel L, Pigeon B, Weill J,
Yigit S, Brauner R, Leger J, Heinrich JJ, Enjalbert A, Brue T, Drouin J 2004 A neonatal form of
isolated ACTH deficiency frequently associated with Tpit gene mutations. Endocr Res
30:943-944
126.
Fassnacht M, Kenn W, Allolio B 2004 Adrenal tumors: how to establish malignancy ? J
Endocrinol Invest 27:387-399
127.
Hansen IA, Fassnacht M, Hahner S, Hammer F, Schammann M, Meyer SR, Bicknell AB,
Allolio B 2004 The adrenal secretory serine protease AsP is a short secretory isoform of the
transmembrane airway trypsin-like protease. Endocrinology 145:1898-1905
128.
Hansen IA, To TT, Wortmann S, Burmester T, Winkler C, Meyer SR, Neuner C, Fassnacht M,
Allolio B 2003 The pro-opiomelanocortin gene of the zebrafish (Danio rerio). Biochem
Biophys Res Commun 303:1121-1128
129.
Saeger W, Fassnacht M, Chita R, Prager G, Nies C, Lorenz K, Barlehner E, Simon D, Niederle
B, Beuschlein F, Allolio B, Reincke M 2003 High diagnostic accuracy of adrenal core biopsy:
results of the German and Austrian adrenal network multicenter trial in 220 consecutive
patients. Hum Pathol 34:180-186
130.
Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F, Troppmair
J, Allolio B 2003 N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor
cells and decreases adrenal steroidogenesis. J Clin Endocrinol Metab 88:2171-2179
131.
Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W 2003 Beyond adrenal and
ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women
with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2760-2766
132.
Fassnacht M, Franke A, Dettling A, Hahner S, Zink M, Wudy S, Allolio B 2002 Clodronate
inhibits adrenocortical cell proliferation and P450c21 activity. J Endocrinol 174:509-516
133.
Saeger W, Fassnacht M, Reincke M, Allolio B 2002 Expression of HER-2/neu receptor
protein in adrenal tumors. Pathol Res Pract 198:445-448
134.
Allolio B, Fassnacht M, Arlt W 2002 [Malignant tumors of the adrenal cortex]. Internist
(Berl) 43:186-195
135.
Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M 2001 Angiotensin II
type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. Clin
Endocrinol (Oxf) 54:627-632
136.
Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler
D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B 2001 Dehydroepiandrosterone
supplementation in healthy men with an age-related decline of dehydroepiandrosterone
secretion. J Clin Endocrinol Metab 86:4686-4692
137.
Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B 2001 Octreotide LAR treatment
throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf) 55:411-415
138.
Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B, Reincke M 2001
Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J
Endocrinol 145:335-341
139.
Beuschlein F, Fassnacht M, Klink A, Allolio B, Reincke M 2001 ACTH-receptor expression,
regulation and role in adrenocortial tumor formation. Eur J Endocrinol 144:199-206
140.
Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B 2001
Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body
composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab
86:1968-1972
141.
Blind E, Fassnacht M, Korber C, Korber-Hafner N, Reiners C, Allolio B 2001 [Severe Vitamin
D(dihydrotachysterol)-intoxication with temporary anemia and hypercalcemia responsive
to bisphosphonates]. Dtsch Med Wochenschr 126:T21-T24
142.
Fassnacht M, Hahner S, Beuschlein F, Klink A, Reincke M, Allolio B 2000 New mechanisms of
adrenostatic compounds in a human adrenocortical cancer cell line. Eur J Clin Invest 30
Suppl 3:76-82
143.
Beuschlein F, Borgemeister M, Schirra J, Goke B, Fassnacht M, Arlt W, Allolio B, Reincke M
2000 Oral glucose tolerance testing but not intravenous glucose administration uncovers
hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal
incidentalomas. Clin Endocrinol (Oxf) 52:617-623
144.
Zenkert S, Schubert B, Fassnacht M, Beuschlein F, Allolio B, Reincke M 2000 Steroidogenic
acute regulatory protein mRNA expression in adrenal tumours. Eur J Endocrinol 142:294299
145.
Fassnacht M, Beuschlein F, Vay S, Mora P, Allolio B, Reincke M 1998 Aminoglutethimide
suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor
cell line. J Endocrinol 159:35-42
146.
Reincke M, Fassnacht M, Vath S, Mora P, Allolio B 1996 Adrenal incidentalomas: a
manifestation of the metabolic syndrome? Endocr Res 22:757-761